Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $595000.0.

  • Syndax Pharmaceuticals' Other Accumulated Expenses rose 18605.77% to $595000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $595000.0, marking a year-over-year increase of 18605.77%. This contributed to the annual value of $421000.0 for FY2024, which is 5259.01% down from last year.
  • Syndax Pharmaceuticals' Other Accumulated Expenses amounted to $595000.0 in Q3 2025, which was up 18605.77% from $618000.0 recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Other Accumulated Expenses ranged from a high of $3.2 million in Q3 2022 and a low of $188000.0 during Q3 2021
  • Over the past 5 years, Syndax Pharmaceuticals' median Other Accumulated Expenses value was $604000.0 (recorded in 2022), while the average stood at $938631.6.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Other Accumulated Expenses skyrocketed by 159468.09% in 2022 and then plummeted by 8313.33% in 2023.
  • Syndax Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $1.7 million in 2021, then crashed by 64.49% to $604000.0 in 2022, then soared by 47.02% to $888000.0 in 2023, then tumbled by 52.59% to $421000.0 in 2024, then soared by 41.33% to $595000.0 in 2025.
  • Its last three reported values are $595000.0 in Q3 2025, $618000.0 for Q2 2025, and $576000.0 during Q1 2025.